KAIST Uncovers the “Hidden Key” to Immunotherapy for Intractable Brain Tumors (IMAGE)

The Korea Advanced Institute of Science and Technology (KAIST)

KAIST Uncovers the “Hidden Key” to Immunotherapy for Intractable Brain Tumors

Caption

Figure 1. Proposed model. In glioma-bearing mice, anti-CTLA-4 treatment increases inducible T cell costimulator (ICOS) expression on CD4 T cells and expands T follicular helper (TFH) cells in tumor-draining dcLNs. Enhanced TFH responses promote the expansion of germinal center (GC) B cells, leading to clonal expansion and class switching. This induces glioma-reactive IgG production, which binds glioma cells and enhances phagocytosis by tumor-infiltrating myeloid cells, contributing to glioma control. Graphics created with BioRender

Credit

KAIST

Usage Restrictions

No

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.